NewEdge Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $137M | Buy |
632,140
+5,648
| +0.9% | +$1.25M | 0.5% | 42 |
|
|
2025
Q4 | $143M | Buy |
626,492
+45,300
| +8% | +$10.3M | 0.52% | 36 |
|
|
2025
Q3 | $135M | Buy |
581,192
+25,619
| +5% | +$5.22M | 0.61% | 24 |
|
|
2025
Q2 | $103M | Buy |
555,573
+45,537
| +9% | +$8.46M | 0.53% | 28 |
|
|
2025
Q1 | $107M | Buy |
510,036
+12,783
| +3% | +$2.49M | 0.63% | 22 |
|
|
2024
Q4 | $88.4M | Buy |
497,253
+44,335
| +10% | +$8.15M | 0.53% | 30 |
|
|
2024
Q3 | $89.4M | Buy |
452,918
+11,007
| +2% | +$2.05M | 0.58% | 26 |
|
|
2024
Q2 | $75.8M | Buy |
441,911
+51,874
| +13% | +$8.59M | 0.55% | 30 |
|
|
2024
Q1 | $71M | Buy |
390,037
+1,565
| +0.4% | +$270K | 0.62% | 23 |
|
|
2023
Q4 | $61.4M | Buy |
388,472
+3,037
| +0.8% | +$443K | 0.58% | 22 |
|
|
2023
Q3 | $57.5M | Buy |
385,435
+49,902
| +15% | +$7.33M | 0.63% | 21 |
|
|
2023
Q2 | $45.2M | Buy |
335,533
+210,289
| +168% | +$30.8M | 0.51% | 34 |
|
|
2023
Q1 | $19.6M | Sell |
125,244
-323
| -0.3% | -$49.4K | 0.25% | 100 |
|
|
2022
Q4 | $11.3M | Buy |
125,567
+5,830
| +5% | +$894K | 0.3% | 75 |
|
|
2022
Q3 | $16.1M | Buy |
119,737
+1,763
| +1% | +$253K | 0.26% | 99 |
|
|
2022
Q2 | $18.1M | Sell |
117,974
-3,542
| -3% | -$541K | 0.3% | 84 |
|
|
2022
Q1 | $19.7M | Buy |
121,516
+20,102
| +20% | +$2.92M | 0.32% | 73 |
|
|
2021
Q4 | $13.7M | Buy |
101,414
+45,909
| +83% | +$5.42M | 0.21% | 112 |
|
|
2021
Q3 | $5.99M | Buy |
55,505
+9,344
| +20% | +$1.07M | 0.15% | 143 |
|
|
2021
Q2 | $5.2M | Buy |
46,161
+5,887
| +15% | +$663K | 0.14% | 154 |
|
|
2021
Q1 | $4.36M | Buy |
40,274
+2,157
| +6% | +$231K | 0.13% | 170 |
|
|
2020
Q4 | $4.08M | Sell |
38,117
-2,291
| -6% | -$220K | 0.13% | 157 |
|
|
2020
Q3 | $3.54M | Buy |
40,408
+4,227
| +12% | +$398K | 0.12% | 169 |
|
|
2020
Q2 | $3.55M | Buy |
36,181
+6,173
| +21% | +$544K | 0.14% | 144 |
|
|
2020
Q1 | $2.29M | Sell |
30,008
-9,759
| -25% | -$831K | 0.11% | 176 |
|
|
2019
Q4 | $3.52M | Buy |
39,767
+1,550
| +4% | +$129K | 0.14% | 165 |
|
|
2019
Q3 | $2.9M | Buy |
38,217
+3,060
| +9% | +$210K | 0.13% | 162 |
|
|
2019
Q2 | $2.56M | Sell |
35,157
-1,359
| -4% | -$107K | 0.16% | 144 |
|
|
2019
Q1 | $2.94M | Sell |
36,516
-11,324
| -24% | -$926K | 0.19% | 130 |
|
|
2018
Q4 | $4.41K | Buy |
47,840
+1,443
| +3% | +$127K | 0.28% | 88 |
|
|
2018
Q3 | $4.39M | Buy |
46,397
+8,929
| +24% | +$847K | 0.34% | 80 |
|
|
2018
Q2 | $3.49K | Buy |
37,468
+16,131
| +76% | +$1.58M | 0.32% | 87 |
|
|
2018
Q1 | $1.95M | Buy |
21,337
+1,609
| +8% | +$177K | 0.22% | 100 |
|
|
2017
Q4 | $1.96M | Buy |
19,728
+91
| +0.5% | +$8.58K | 0.27% | 84 |
|
|
2017
Q3 | $1.78M | Sell |
19,637
-1,412
| -7% | -$107K | 0.28% | 87 |
|
|
2017
Q2 | $1.51M | Buy |
21,049
+6,626
| +46% | +$445K | 0.26% | 89 |
|
|
2017
Q1 | $934K | Sell |
14,423
-296
| -2% | -$18.6K | 0.21% | 107 |
|
|
2016
Q4 | $902K | Buy |
14,719
+2,796
| +23% | +$171K | 0.25% | 85 |
|
|
2016
Q3 | $752K | Buy |
11,923
+4,599
| +63% | +$298K | 0.24% | 87 |
|
|
2016
Q2 | $457K | Buy |
+7,324
| New | +$446K | 0.19% | 97 |
|
Other funds holding ABBV
VCM
VPM
NewEdge Advisors's ABBV Position: Q1 2026 in Review
NewEdge Advisors increased its AbbVie (ABBV) stake by 0.9% in Q1 2026, buying an estimated $1.25M and bringing the position to 632,140 shares worth $137M. The position accounts for 0.5% of the portfolio, ranked #42.
NewEdge Advisors first reported a position in ABBV in Q2 2016 and has held it in 40 quarters since. The position peaked at $143M in Q4 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- NewEdge Advisors held 632,140 shares of AbbVie worth $137M as of Q1 2026.
- NewEdge Advisors bought 5,648 AbbVie shares in Q1 2026, an estimated $1.25M.
- AbbVie made up 0.5% of NewEdge Advisors's portfolio in Q1 2026, its #42 holding.
- NewEdge Advisors first reported a position in AbbVie in Q2 2016 and has held it in 40 quarters since.
- NewEdge Advisors's AbbVie position peaked at $143M in Q4 2025.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.